Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia

Ferrajoli, Alessandra; Shanafelt, Tait D.; Ivan, Cristina; Shimizu, Masayoshi; Rabe, Kari G.; Nouraee, Nazila; Ikuo, Mariko; Ghosh, Asish K.; Lerner, Susan; Rassenti, Laura Z.; Xiao, Lianchun; Hu, Jianhua; Reuben, James M.; Calin, Steliana; You, M. James; Manning, John T.; Wierda, William G.; Estrov, Zeev; O’Brien, Susan; Kipps, Thomas J.; Keating, Michael J.; Kay, Neil E.; Calin, George A.

doi:10.1182/blood-2013-01-478222

Cited by 187 publications

(175 citation statements)

References 40 publications

Supporting

Mentioning

157

Contrasting

Unclassified

Order By: Relevance

“…These findings suggest that miR‐21 might function as a biomarker for the diagnosis of DLBCL. Our previous studies showed that miR‐155 was significantly overexpressed in monoclonal B‐cell lymphocytosis (MBL) when compared with normal B cells and that miR‐155 overexpression in plasma is a predictor of poor response to therapy (Ferrajoli et al ., 2013). Similar studies have reported that miR‐150 and miR‐342 were significantly downregulated in the plasma of acute myeloid leukemia (AML) patients at diagnosis compared to healthy controls and that these microRNAs are candidate biomarkers and potential predictors of relapse in AML (Fayyad‐Kazan et al ., 2013).…”

Section: Circulating Mirnas As Biomarkersmentioning

confidence: 99%

Cell‐to‐cell communication: microRNAs as hormones

2017

Self Cite

View full text Add to dashboard Cite

Mammalian cells can release different types of extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies. Accumulating evidence suggests that EVs play a role in cell‐to‐cell communication within the tumor microenvironment. EVs’ components, such as proteins, noncoding RNAs [microRNAs (miRNAs), and long noncoding RNAs (lncRNAs)], messenger RNAs (mRNAs), DNA, and lipids, can mediate paracrine signaling in the tumor microenvironment. Recently, miRNAs encapsulated in secreted EVs have been identified in the extracellular space. Mature miRNAs that participate in intercellular communication are released from most cells, often within EVs, and disseminate through the extracellular fluid to reach remote target cells, including tumor cells, whose phenotypes they can influence by regulating mRNA and protein expression either as tumor suppressors or as oncogenes, depending on their targets. In this review, we discuss the roles of miRNAs in intercellular communication, the biological function of extracellular miRNAs, and their potential applications for diagnosis and therapeutics. We will give examples of miRNAs that behave as hormones.

show abstract

Section: Circulating Mirnas As Biomarkersmentioning

confidence: 99%

Cell‐to‐cell communication: microRNAs as hormones

2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…64 In addition, exosomal miR-21 and miR-29a were demonstrated to stimulate Toll-like receptor-7 and -8, causing a prometastatic inflammatory response and activating tumor growth and metastasis. 65 Furthermore, Ferrajoli et al 66 described an overexpression of miR-155 in free circulating and blood microvesicles for MBL (monoclonal B-cell lymphocytosis) and CLL (chronic lymphocytic leukemia) patients. Separately, in another study, 11 exosomal miRNAs were observed overexpressed in prostate cancer patients and miR-141 and miR-375 were presented as potential markers of metastatic prostate cancer based on exosomal and microvesicle samples.…”

Section: Exosomal Mirnas In Cancermentioning

confidence: 99%

“…66 For example, increased levels of exosomal miR-141 and miR-375 were capable of predicting metastasis or disease recurrence in prostate cancer. 91 Exosomal miRNAs have shown distinct profiles in ovarian cancer versus benign ovarian tumors.…”

Section: Exosomes As Novel Cancer Biomarkersmentioning

confidence: 99%

Exosomes as divine messengers: are they the Hermes of modern molecular oncology?

et al. 2014

View full text Add to dashboard Cite

Exosomes are cell-derived vesicles that convey key elements with the potential to modulate intercellular communication. They are known to be secreted from all types of cells, and are crucial messengers that can regulate cellular processes by 'trafficking' molecules from cells of one tissue to another. The exosomal content has been shown to be broad, composed of different types of cytokines, growth factors, proteins, or nucleic acids. Besides messenger RNA (mRNA) they can also contain noncoding transcripts such as microRNAs (miRNAs), which are small endogenous cellular regulators of protein expression. In diseases such as cancer, exosomes can facilitate tumor progression by altering their vesicular content and supplying the tumor niche with molecules that favor the progression of oncogenic processes such as proliferation, invasion and metastasis, or even drug resistance. The packaging of their molecular content is known to be tissue specific, a fact that makes them interesting tools in clinical diagnostics and ideal candidates for biomarkers. In the current report, we describe the main properties of exosomes and explain their involvement in processes such as cell differentiation and cell death. Furthermore, we emphasize the need of developing patient-targeted treatments by applying the conceptualization of exosomal-derived miRNA-based therapeutics.

show abstract

“…A number of studies have shown deregulation of exosomal-miRNA levels as a potential biomarker for cancer [150]. For example, exosomal levels of miR-141 and miR-375 can be used to predict metastasis or the recurrence of disease in prostate cancer [151].…”

Section: Liquid Biopsies-the Future?mentioning

confidence: 99%

Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer

Sacco

Al‐Akhrass²,

Wilson

2016

CPD

View full text Add to dashboard Cite

Lung cancer is the most common cause of cancer-related death worldwide, causing over 1.2 million deaths each year. Non-small-cell lung cancer (NSCLC) consists of a group of malignancies that are pathologically and molecularly diverse but that are all characterised by a poor prognosis. Survival rates for lung cancer patients have improved very slowly and only to a modest degree owing partly to poor funding for research into this malignancy and stigma associated with smoking, as well as relative chemo-resistance. However, in recent years, NSCLC has become an exemplar for precision medicine, mainly following development of drugs targeting the receptors of epidermal growth factor and anaplastic lymphoma kinase. While epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors are only applicable to a minority of patients and benefits are almost invariably short-lived, current studies indicate that at least 50% of patients with NSCLC have a targetable mutation. With a growing armamentarium of inhibitors against these targets in development, there is a hope that a greater proportion of patients will benefit from precision medicine and that such benefits will be sustained. However, there remain significant challenges in the development of precision medicine in NSCLC. These include: identification and validation of new targets; ensuring biopsies are fit for purpose; tumour heterogeneity; requirements for serial tumour assessments; and not least cost. In this review, we will discuss the current status of precision medicine in NSCLC as well as how basic and translational research are paving the way towards overcoming the above challenges. In addition, we will pay attention to clinical

show abstract

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia

Cited by 187 publications

References 40 publications

Cell‐to‐cell communication: microRNAs as hormones

Cell‐to‐cell communication: microRNAs as hormones

Exosomes as divine messengers: are they the Hermes of modern molecular oncology?

Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer

Contact Info

Product

Resources

About